A proposal will soon be considered to centralize licensing for all sterile drug products. This move aims to tighten regulations on medicines prone to microbial contamination. Currently, only specific sterile medicines fall under central licensing authority. The proposal highlights fragmented existing frameworks and varying state inspection practices. Bringing all sterile products under central oversight will create a uniform regulatory system.